Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

WASHINGTON (AP) — Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Pfizer secures a $10 billion deal to acquire Metsera, outbidding Novo Nordisk. The move boosts Pfizer’s presence in the fast-growing obesity drug market, signaling a major strategic comeback.

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.